ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient-reported outcome measures"

  • Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium

    The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

    Rebecca Trachtman1, Daniel J. Lovell 2, Rula Issa 1, Stephanie Pan 1, Karen Wilson 1 and Karen Onel 3, 1Icahn School of Medicine at Mount Sinai, New York, 2Cincinnati, 3Hospital for Special Surgery, New York

    Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
  • Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium

    Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life

    Mariana Correia Marques1, Nicole Tennermann 2, Sivia Lapidus 3, Grant Schulert 4, Jennifer Tousseau 2, Rashmi Sinha 5, Karen Durrant 6, Saskya Angevare 7 and Fatma Dedeoglu 8, 1Boston Children's Hospital, Boston, Massachusetts, 2, 3The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, 4Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, 5Systemic JIA Foundation, Cincinnati, 6Autoinflammatory Alliance, San Francisco, 7Amersfoort, Netherlands, 8Boston Children's Hospital, Boston

    Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response.  The variability in…
  • Abstract Number: 422 • 2019 ACR/ARP Annual Meeting

    The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis

    Vibeke Strand1, Pankaj Patel 2, Naijun Chen 2 and Elizabeth M Lesser 3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., North Chicago

    Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
  • Abstract Number: 1250 • 2019 ACR/ARP Annual Meeting

    Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?

    Emre Bilgin 1, Timuçin Kaşifoğlu 2, Ahmet Omma 3, Cemal Bes 4, Muhammet Çınar 5, Hakan Emmungil 6, Orhan Küçükşahin 7, Servet Akar 8, Kenan Aksu 9, Fatih Yıldız 10, Nilüfer Kanıtez 11, Abdulsamet Erden 12, Sezin Turan 13, Ediz Dalkılıç 14, Selime Ermurat 15, Mutlu Hayran 16 and Umut Kalyoncu17, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, 3Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4University of Medical Sciences, İstanbul, Turkey, 5University of Medical Sciences, Ankara, Turkey, 6Trakya University, Edirne, Turkey, 7Liv Hospital, Ankara, Turkey, 8Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 9Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 10Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaraş, Turkey, 11Koç University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 12Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 13Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey, 14Uludağ University, Bursa, Turkey, 15Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, 16Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, 17Hacettepe University Department of Rheumatology, Ankara, Turkey

    Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare, chronic and auto-inflammatory disorder with multisystemic involvement. Patient Acceptable Symptom State (PASS) is the highest level of…
  • Abstract Number: 424 • 2019 ACR/ARP Annual Meeting

    A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index

    Tyler Harkness1, Karen Donelan 1, Xiaoqing Fu 1, Rachel Wallwork 1, Cory Perugino 1, John Stone 2 and Zachary Wallace 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) causes symptoms, the severity of which vary by organ involvement. The Responder Index (RI) captures physicians’ judgement of disease activity, but…
  • Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting

    Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies

    Martin Bergman1, Namita Tundia 2, Heidi Camp 2, Sebastian Meerwein 3, Casey Schlacher 2, Debbie Goldschmidt 4, Yan Song 5 and Vibeke Strand 6, 1Drexel University College of Medicine, Stockholm, Sweden, 2AbbVie Inc., North Chicago, IL, 3AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, 4Analysis Group, Inc., New York, NY, 5Analysis Group, Inc., Boston, MA, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
  • Abstract Number: 428 • 2019 ACR/ARP Annual Meeting

    Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus

    Srita Chakka1, Rebecca Krain 1, Sarah Ahmed 2, Josef Concha 1, Rui Feng 3 and Victoria Werth 4, 1University of Pennsylvania, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, 4Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA

    Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
  • Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting

    Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study

    Roy Fleischmann1, Martin Bergman 2, Namita Tundia 3, In-Ho Song 4, Jessica Suboticki 4, Yan Song 5 and Vibeke Strand 6, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Drexel University College of Medicine, Stockholm, Sweden, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 5Analysis Group, Inc., Boston, MA, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
  • Abstract Number: 431 • 2019 ACR/ARP Annual Meeting

    Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

    Michiel Luijten 1, Caroline Terwee 2, Hedy van Oers 2, Mala Joosten 3, Merlijn van den Berg 2, Dieneke Schonenberg-Meinema 2, Koert Dolman 4, Rebecca Ten Cate 5, Leo Roorda 6, Martha Grootenhuis 3, Marion van Rossum7 and Lotte Haverman 2, 1Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, 4Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, 5Leiden University Medical Centre, Leiden, Netherlands, 6Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, 7Amsterdam University Medical Centers, Amsterdam

    Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
  • Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting

    Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials

    Vibeke Strand1, Namita Tundia 2, Alan Friedman 3, Heidi Camp 2, Jessica Suboticki 4, Debbie Goldschmidt 5, Catherine Fernan 5 and Martin Bergman 6, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., North Chicago, 4AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, 5Analysis Group, Inc., New York, NY, 6Drexel University College of Medicine, Stockholm, Sweden

    Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
  • Abstract Number: 433 • 2019 ACR/ARP Annual Meeting

    Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis

    Ruchi Patel 1, Valeria Esparza 2, Jin-Shei Lai 1, Elizabeth Gray 1, Rowland Chang 3, David Cella 3 and Kaveh Ardalan4, 1Northwestern University Feinberg School of Medicine, Chicago, 2University of Illinois-Chicago College of Medicine, Chicago, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

    Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
  • Abstract Number: 1423 • 2019 ACR/ARP Annual Meeting

    Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Joe Zhuo 7, Kuan-Hsiang Gary Huang 8, Robert Wong 7, Sean Connolly 8, Yedid Elbez 9 and Roy Fleischmann 10, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, 8Bristol-Myers Squibb, Princeton, NJ, 9Excelya, Boulogne-Billancourt, France, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Early biologic use can improve long-term control of RA, and early use of abatacept (ABA) + MTX has demonstrated sustained improvements in selected patient-reported…
  • Abstract Number: 435 • 2019 ACR/ARP Annual Meeting

    Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower

    W. Benjamin Nowell1, Carol Gaich 2, Kelly Gavigan 1, Zhihong Cai 2, Anabela Cardoso 2, Theresa Hunter 3, Julie Birt 2, Jennifer Workman 2 and Jeffrey Curtis 4, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Eli Lilly and Company, Indianapolis, IN, 3Eli Lilly and Company, Indianapolis, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patient-reported outcomes (PROs) are important indicators of treatment effectiveness and their role is increasing in comparative effectiveness studies. Little is known about PRO measures…
  • Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting

    Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome

    Eun Hye Park1, You-Jung Ha 1, Eun Ha Kang 1, Yeong-Wook Song 2 and Yun Jong Lee 3, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, 2Seoul National University Hospital, Seoul, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea

    Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
  • Abstract Number: 441 • 2019 ACR/ARP Annual Meeting

    Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain

    Rosa Morlà1, R. Castellanos 2, Virginia Ruiz-Esquide 3, Julio Ramirez 4, Raimon Sanmarti 5, Jose Gomez-Puerta 5, Mariam Riad 6, Isabel Castrejon 6 and Theodore Pincus 6, 1Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, 2Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, 3Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 4Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 5Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 6Division of Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported.  We compared MDHAQ (multidimensional health…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology